These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 12238004)

  • 21. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coronary bifurcation stenting. Current techniques, outcome and possible future developments.
    Melikian N; Airoldi F; Di Mario C
    Minerva Cardioangiol; 2004 Oct; 52(5):365-78. PubMed ID: 15514572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymer-sirolimus-eluting stents in de novo lesions.
    Schuler G
    Herz; 2004 Mar; 29(2):152-61. PubMed ID: 15057437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia.
    Brito FS; Rosa WC; Arruda JA; Tedesco H; Pestana JO; Lima VC
    Catheter Cardiovasc Interv; 2005 Apr; 64(4):413-8. PubMed ID: 15789385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late incomplete lesion coverage following Cypher stent deployment for diffuse right coronary artery stenosis.
    Halkin A; Carlier S; Leon MB
    Heart; 2004 Aug; 90(8):e45. PubMed ID: 15253987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
    Sabaté M; Jiménez-Quevedo P; Angiolillo DJ; Gómez-Hospital JA; Alfonso F; Hernández-Antolín R; Goicolea J; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Circulation; 2005 Oct; 112(14):2175-83. PubMed ID: 16203930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left main coronary artery stenting: crossing the Rubicon.
    Alfonso F
    J Am Coll Cardiol; 2009 May; 53(19):1769-72. PubMed ID: 19422983
    [No Abstract]   [Full Text] [Related]  

  • 29. Bifurcation intervention: is it crush time yet?
    Williams DO; Abbott JD
    J Am Coll Cardiol; 2005 Aug; 46(4):621-4. PubMed ID: 16098425
    [No Abstract]   [Full Text] [Related]  

  • 30. Promoting vascular regeneration as an alternative to conventional angioplasty-based intervention.
    Noordeloos AM; Soullié T; Duckers HJ; Serruys PW
    Endothelium; 2006; 13(6):431-9. PubMed ID: 17169775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug-eluting stents: efficacy, effectiveness, efficiency and evidence].
    Lázaro y de Mercado P
    Rev Esp Cardiol; 2004 Jul; 57(7):608-12. PubMed ID: 15274844
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
    Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi-lesion culotte and crush bifurcation stenting with sirolimus-eluting stents: long-term angiographic outcome.
    Daemen J; Lemos PA; Serruys PW
    J Invasive Cardiol; 2003 Nov; 15(11):653-6. PubMed ID: 14608139
    [No Abstract]   [Full Text] [Related]  

  • 34. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.
    Scheller B; Speck U; Abramjuk C; Bernhardt U; Böhm M; Nickenig G
    Circulation; 2004 Aug; 110(7):810-4. PubMed ID: 15302790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The "0%" restenosis study.
    Colombo A
    Ital Heart J; 2002 Oct; 3(10):559-6. PubMed ID: 12478812
    [No Abstract]   [Full Text] [Related]  

  • 37. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards defining the role of drug eluting stents.
    Tarantini G; Ramondo A; Razzolini R
    Minerva Cardioangiol; 2008 Feb; 56(1):29-34. PubMed ID: 18432166
    [No Abstract]   [Full Text] [Related]  

  • 39. Restenosis related to percutaneous coronary intervention has been solved?
    Kivelä A; Hartikainen J
    Ann Med; 2006; 38(3):173-87. PubMed ID: 16720432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How many grails do we need?
    Holmes DR
    Circulation; 2004 May; 109(18):2158-9. PubMed ID: 15136508
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.